Manish Kohli

Cost-Effectiveness Analysis of seven treatments In Metastatic Hormone-Sensitive Prostate Cancer (mHSPC): A Public-Payer Perspective academic.oup.com/jnci/article-a… - In the background of a lack of predictive biomarkers and head-to-head comparisons

Cancer heterogeneity at the molecular level evolves continuously and, in most cases, ferociously from local to metastatic states. Machine-Learning #ML application successfully captures a molecular signature in blood that is based on a set of genomic (#ctD…lnkd.in/gbssRUA9

Privileged to visit and present at the #CanaryCenter at #stanforduniversity "Early Detection Seminar Series" and foster current and future research collaborations between #huntsmancancerinstitute, #universityofutah and #stanforduniversity . Fantastic po…lnkd.in/g78rakKJ

Dearth of molecular predictive/prognostic bio markers in metastatic hormone-sensitive prostate cancer (mHSPC) is an existential challenge in the clinics. In a joint collaborative effort between #HuntsmanCancerInstitute at #universityofutah and #MoffittCa…lnkd.in/gAzAw7u8

The value of fusing clinically useful genomic tumor-specific, state-relevant molecules with emerging ultra sensitive technologies (Quantum Dots) potentially enhances multiplexing capacities using qPCR for cancer care in future. Presented at #aacr2023 as a…lnkd.in/grfK8iFu

Excellent portal of high quality educational series and discussions on myeloma!! lnkd.in/g5D3pCfr

With so many first line FDA approved (costly) treatments available for patients with kidney cancer that has spread, there is considerable confusion amongst cancer experts on choosing one over the other. There are no clear validat…lnkd.in/gVd-VGfR lnkd.in/gZvPF3JH

Our team published a plasma Copy Number Alteration (CNA)-Based Prognostic and Predictive Multi-Gene Risk Scores in Metastatic Castration-Resistant Prostate Cancer using two independent cohorts. Ability to predict clinical outcomes…lnkd.in/gKf8c4Zi lnkd.in/gvyMd47B

Starting work on my 5th NIH funded RO1 in #cancerresearch - this time working on a different theme with gifted colleagues at U of Utah/Huntsman Cancer Institute, U. Michigan and Fred Hutch and on a theme to improve detection of cancer recurrences in #pro…lnkd.in/gFcSvnHc

@KLM I replied

@KohliMask1020 Did you already go to the transfer desk? Please share your full name, booking code and ticket number via a Direct Message in case you have further questions.

Stuck at BHX with technical fault in plane; multiple missed connections; no customer service or updates on when we can get back home. It has been over 7 hours. Shabby job @KLM @Delta!

Our @ASCO_pubs #JCOPO paper on prognostic utility of PI3K and AR pathway aberrations in #ProstateCancer #LiquidBiopsy is out today! Congrats to @EdmondMKwan for leading a team of amazing collaborators bit.ly/3wzjrEe 🧵1/8

@itsnot_pink Yes- the “luck” factor is still relevant as there is so much we still need to know at the individual pt level in order to prescribe/ treat/manage. Hope researchers keep working on how to peel down the unknown more and treat in an even more smarter way!

To people w cancer giving motivational talks: You can talk about your determination & your medical team’s abilities, but PLEASE recognize LUCK played a role in you still being alive. So many of my friends who died did everything right, “fought harder,” but that wasn’t enough.

#GU21 @ASCO Very proud to see my dear friend Dr. Jonathan Tward @prostatemd @huntsmancancer @Huntsman_GU giving this excellent talk 👉Prolaris test may allow some pts with localized @prostatecancer avoid androgen deprivation Rx. Must watch @DrPaulNguyen @OncoAlert @PCF_Science

@InadomiJ @mzmolnar @neerajaiims @KenGrossmannMD @SiwenONC @umangtalking @maughanonc @EAMiddleton5 @RondinaLab Energetic and passionate gp @ U of U- HCI

(2/2) @mzmolnar @KohliMask1020 @neerajaiims @KenGrossmannMD @SiwenONC @umangtalking @maughanonc @EAMiddleton5 @RondinaLab and any others I may have missed or are not a part of the Twitter-sphere. #MedicineElevated #ResearchElevated

(1/2) Another round of fantastic top research publications across our department is now available! Thanks to our research contributors: @StavrosDrakos @rranjanMD @msamore @DuVallScott @AndrewGawron @MInczeMD @TimFarrell_MD @heme_fan @laura_certain medicine.utah.edu/internalmedici…

@NicoleKuderer @neerajaiims @OncoAlert @NeliMUlrich @DrChoueiri @montypal @PGrivasMDPhD @VivekSubbiah @ADesaiMD @umangtalking @cdanicas @GGiannarini @gary_lyman Hi Nicole- Hope all has been well with you/Gary! (still learning twitter- apologies for the late replay); would love to see you here in Utah as Neli mentioned! Best regards!

FDA expected to approve Moderna's Covid vaccine for use in the United States today👏👏. Which one to take ??Key difference in the side effects, characteristics of Moderna versus Pfizer vaccine & MOA.👇👇@OncoAlert

The Identification of Plasma Exosomal miR-423-3p as a Potential Predictive Biomarker for Prostate Cancer Castration… pubmed.ncbi.nlm.nih.gov/33490068/ Pleasure to participate in this international collaboration! Additional evidence of the clinical value miRs in mCRPC!

mdpi.com/search?authors… via @MDPIOpenAccess We observed that plasma progastrin (hPG80) is detected in 94% of mRCCC patients and hPG80 levels significantly enhance the prognostic performance of IMDC in mRCCC. Need more prospective validation

Must read in @JCO_ASCO today-> brilliant insights on the biology underneath differential efficacy of PARP inhibitors in #prostatecancer with BRCA1 vs. BRCA2 mutations 👇by @EAntonarakis @MarkowskiGUOnc @HopkinsMedicine Weblink👉🏻 bit.ly/3bhJDcv @OncoAlert @urotoday